Biogen Inc. Common Stock

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% ...

Grey Matters Health Inc. has received its first brain-dedicated PET scanning system (CareMiBrain) for its flagship NovaScan Neuroimaging Clinic in Davie, Florida, positioning itself as the first U.S. clinic to offer brain-only PET scans for early Alzheimer's detection. The clinic will capitalize on the emerging billion-dollar market created by FD...

Biogen announced a $1 billion acquisition of RayThera, a company with anti-inflammatory assets targeting immune-mediated conditions. This strategic move strengthens Biogen's immunology portfolio following its earlier acquisition of Apellis Pharmaceuticals. The company is successfully transitioning from its declining MS drug business to growth are...

A federal court has approved an $18.9 million settlement for investors who purchased Biogen Inc. common stock between June 8, 2021 and July 12, 2021. A settlement hearing is scheduled for September 29, 2026, to determine if the settlement is fair and reasonable. Class members must submit a Proof of Claim by September 24, 2026 to receive compensat...

Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement of Phase 2 CELIA study results for diranersen (BIIB080), an Alzheimer's disease treatment. Although Biogen described the results as 'compelling,' the study missed its primary dose-response endpoint, causing the stock to fall $13.16 per s...